Shots:

• The approval follows 24 wks. a pediatric study assessing Gattex (teduglutide- 0.025/0.05 mg/kg/day) vs SOC in 68 patients with SBS aged ≥ 1 yrs. who are dependent on parenteral support (PS)
• The study resulted in 69% reduction in PS vol. by 20%+- 42% mean reduction in PS volume- 38% reduction in PS infusion by at least 1day/wk.- reduction in PS infusion time by 3hrs.- 12% completely weaned off PS
• Gattex (teduglutide- IV) is an approved GLP-2 analog- helping the intestine to absorb nutrients and reducing the dependency on PS and is indicated both in adults & pediatric patients for SBS

Ref: Takeda | Image: Takeda